多黏菌素类抗生素的肾毒性(4)
[13] Akajagbor DS， Wilson SL， Shere-Wolfe KD， et al. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center [J]. Clin Infect Dis， 2013， 57(9)： 1300-1303.
[14] Tuon FF， Rigatto MH， Lopes CK， et al. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium [J]. Int J Antimicrob Agents， 2014， 43(4)： 349-352.
[15] Mendes CA， Cordeiro JA， Burdmann EA. Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use [J]. Ann Pharmacother， 2009， 43(12)： 1948-1955.
[16] Kubin CJ， Ellman TM， Phadke V， et al. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy [J]. J Infect， 2012， 65(1)： 80-87.
[17] Alipour M， Halwani M， Omri A， et al. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains [J]. Int J Pharm， 2007， 355(1-2)： 293-298.
[18] Pattani AS， Mandawgade SD， Patravale VB. Development and comparative anti-microbial evaluation of lipid nanoparticles and nanoemulsion of polymyxin B [J]. J Nanosci Nanotechnol， 2006， 6(9-10)： 2986-2990.
[19] Mingeot-Leclercq MP， Tulkens PM， Denamur S， et al. Novel polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells [J]. Peptides， 2012， 35(2)： 248-252. (孟现民 董平 张永信)
[14] Tuon FF， Rigatto MH， Lopes CK， et al. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium [J]. Int J Antimicrob Agents， 2014， 43(4)： 349-352.
[15] Mendes CA， Cordeiro JA， Burdmann EA. Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use [J]. Ann Pharmacother， 2009， 43(12)： 1948-1955.
[16] Kubin CJ， Ellman TM， Phadke V， et al. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy [J]. J Infect， 2012， 65(1)： 80-87.
[17] Alipour M， Halwani M， Omri A， et al. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains [J]. Int J Pharm， 2007， 355(1-2)： 293-298.
[18] Pattani AS， Mandawgade SD， Patravale VB. Development and comparative anti-microbial evaluation of lipid nanoparticles and nanoemulsion of polymyxin B [J]. J Nanosci Nanotechnol， 2006， 6(9-10)： 2986-2990.
[19] Mingeot-Leclercq MP， Tulkens PM， Denamur S， et al. Novel polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells [J]. Peptides， 2012， 35(2)： 248-252. (孟现民 董平 张永信)